

DEC 15 2004

SCHERING-PLOUGH CORPORATION
LAW DEPARTMENT
2000 GALLOPING HILL ROAD
K-6-1, MAIL STOP 1990
KENILWORTH, NEW JERSEY 07033
(908) 298-4000

FACSIMILE TRANSMITTAL SHEET

TO:

Examiner: D. R. Rao
USPTO

FAX NUMBER:

(703) 872-9306

FROM:

Palaiyur S. Kalyanaraman

PHONE NUMBER:

(908) 298-5068

TOTAL NO. OF PAGES INCLUDING COVER

15

DATE

December 15, 2004

CONFIDENTIALITY NOTE: This sheet and/or the document(s) accompanying it contain information belonging to Schering-Plough Corporation and/or its affiliates which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named above. If you have received this fax in error, please immediately notify us by telephone. If there is a problem with this transmission please call Ashly Armstrong at (908) 298-4025.

NOTES/COMMENTS:

PLEASE HAND DELIVERIn re Application of: K. Paruch *et al.*

For Patent entitled: "Novel Imidazopyrazines as Cyclin Dependent Kinase Inhibitors"

Group Art Unit: 1624

Filed: 09/19/2003

Attorney Docket No.: OC01625K

Serial No.: 10/665,005

Dear Examiner Rao

Transmitted herewith are:

- Fax Cover Sheet – 1pg.
- Response Transmittal (PTO/SB/21) – 1pg.
- Amendment (After Final) – 13 pgs.



Palaiyur S. Kalyanaraman
Registered Representative
Registration No. 34,634

PHONE: (908) 298-5068

FAX: (908) 298-5388


DEC 15 2004


PTO/S&T1 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/665,005	
	Filing Date	09/19/2003	
	First Named Inventor	Kamil Paruch	
	Art Unit	1624	
	Examiner Name	D. R. Rao	
Total Number of Pages in This Submission	15	Attorney Docket Number	OC01625K

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input checked="" type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Remarks	<input type="checkbox"/> After Allowance communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Fax Cover Sheet - 1pg.
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Palaiyur S. Kalyanaraman, Reg. No. 34,634	
Signature		
Date	12/15/2004	

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or printed name	Palaiyur S. Kalyanaraman	
Signature		Date 12/15/2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

DEC 15 2004

PATENT: OC01625K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

5 -----X
In re Application of: :
K. Paruch *et al.* : Examiner: D. R. Rao
: Group Art Unit: 1624
10 Serial No.: 10/665,005 :
Filed: September 19, 2003 : Atty. Docket No.: OC01625K
For: "Novel Imidazopyrazines as Cyclin:
15 Dependent Kinase Inhibitors" :
-----X

Commissioner for Patents
P. O. Box 1450
20 Alexandria, VA 22313-1450

AMENDMENT AFTER FINAL REJECTION PER 37 C.F.R § 1.116

Sir:

25 This communication is in response to the Office Action that the
Examiner issued on November 26, 2004, in the above-identified patent
application. Claims 1, 2, 5-8, 10-12, 17-19 and 25-29 are pending in this case.
Claim 18 is allowed. Claims 1-2, 5-8, 10-12, 17, 19 and 25-29 stand finally
rejected. Applicants respectfully request entry and consideration of the
30 following Amendment and Remarks by Applicants. This Amendment is being
faxed to the Examiner's attention at 703-872-9306.

Amendments to the Claims are reflected in the listing of claims which begins
on page 2 of this paper.

Remarks begin on page 12 of this paper.